AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6161788 — intervention group
Group type: COMPARATOR
Intervention: Control days (no exposure)
Number of subjects: 8
Study 6161788 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower exposure levels
Number of subjects: 8
Study 30706836 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide retard 1.5 mg and valsartan 160 mg in the morning (Group 1)
Number of subjects: 235
Study 30706836 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide retard 1.5 mg in the morning and valsartan 80 mg twice a day (Group 2)
Number of subjects: 235
Study 30706836 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide retard 1.5 mg and valsartan 160 mg in the morning (Group 3)
Number of subjects: 235
Study 30706836 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide retard 1.5 mg in the morning and valsartan 80 mg twice a day (Group 4)
Number of subjects: 235
Study 30706836 — intervention group
Group type: EXPERIMENTAL
Intervention: Double sartan therapy (Group 4)
Number of subjects: 235
Study 28438151 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF)
Number of subjects: 30
Study 28438151 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PRF)
Number of subjects: 30
Study 25416329 — intervention group
Group type: EXPERIMENTAL
Intervention: LCZ696
Number of subjects: 0
Study 25066025 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐SD (Polyethylene glycol 3350 plus sports drink)
Number of subjects: 364
Study 25066025 — intervention group
Group type: COMPARATOR
Intervention: PEG‐ELS (Polyethylene glycol with electrolyte solution)
Number of subjects: 364
Study 25066025 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐SD
Number of subjects: 364
Study 25066025 — intervention group
Group type: COMPARATOR
Intervention: PEG‐ELS
Number of subjects: 364
Study 22210755 — intervention group
Group type: EXPERIMENTAL
Intervention: Etravirine 400 mg once daily
Number of subjects: 157
Study 22210755 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz 600 mg once daily
Number of subjects: 157
Study 22210755 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir/lamivudine
Number of subjects: 157
Study 22210755 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz
Number of subjects: 157
Study 19542736 — intervention group
Group type: EXPERIMENTAL
Intervention: High responders (HR) to ACTH1-24
Number of subjects: 90
Study 19542736 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate responders (IR) to ACTH1-24
Number of subjects: 90
Study 19542736 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal responders (NR) to ACTH1-24
Number of subjects: 90
Study 19542736 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 90
Study 17445476 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of 0.001% NO gas with air, twice daily (AM and PM each for an hour)
Number of subjects: 47
Study 17445476 — intervention group
Group type: COMPARATOR
Intervention: Routine medical treatment (oxygen, aminophylline, dexamethasone, and furosemide)
Number of subjects: 47
Study 15006577 — intervention group
Group type: EXPERIMENTAL
Intervention: Video feedback alone
Number of subjects: 29
Study 15006577 — intervention group
Group type: EXPERIMENTAL
Intervention: Video feedback with the help of an expert
Number of subjects: 29
Study 15006577 — intervention group
Group type: COMPARATOR
Intervention: No feedback
Number of subjects: 29
Study 16624192 — intervention group
Group type: EXPERIMENTAL
Intervention: Dinoprostone (6 hourly intervals up to two doses)
Number of subjects: 226
Study 16624192 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracervical Foley catheter
Number of subjects: 226
Study 16624192 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (50 microg oral, 4 hourly to a maximum of four doses)
Number of subjects: 226
Study 16624192 — intervention group
Group type: EXPERIMENTAL
Intervention: All three agents (Dinoprostone, Foley catheter, Misoprostol)
Number of subjects: 226
Study 10545434 — intervention group
Group type: EXPERIMENTAL
Intervention: VVI pacing for 3 months
Number of subjects: 30
Study 10545434 — intervention group
Group type: EXPERIMENTAL
Intervention: Reestablishment of AV synchrony with DDD pacing after VVI pacing
Number of subjects: 30
Study 10545434 — intervention group
Group type: COMPARATOR
Intervention: DDD pacing for 3 months
Number of subjects: 30
Study 9026379 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol 30 mg, p.o.
Number of subjects: 23
Study 9026379 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 2068470 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin plus aztreonam (900 mg clindamycin + 1 g aztreonam)
Number of subjects: 312
Study 2068470 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin plus cefotaxime (900 mg clindamycin + 1 g cefotaxime)
Number of subjects: 312
Study 2068470 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin plus aztreonam
Number of subjects: 312
Study 2068470 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin plus cefotaxime
Number of subjects: 312
Study 2068470 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime
Number of subjects: 312
Study 6337676 — intervention group
Group type: EXPERIMENTAL
Intervention: PTFE (Goretex)
Number of subjects: 104
Study 6337676 — intervention group
Group type: COMPARATOR
Intervention: Human umbilical vein (Biograft)
Number of subjects: 104
Study 31583951 — intervention group
Group type: EXPERIMENTAL
Intervention: Working Memory (WM) training group
Number of subjects: 31
Study 31583951 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU) control group
Number of subjects: 31
Study 28453221 — intervention group
Group type: EXPERIMENTAL
Intervention: Short implants (6 mm)
Number of subjects: 2
Study 28453221 — intervention group
Group type: COMPARATOR
Intervention: Long implants (10 mm)
Number of subjects: 2
Study 26424170 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin plus metformin
Number of subjects: 1545
Study 26424170 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride plus metformin
Number of subjects: 1545
Study 25090264 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing the dose of metformin (500 mg/day)
Number of subjects: 70
Study 25090264 — intervention group
Group type: COMPARATOR
Intervention: Add-on sitagliptin (50 mg/day)
Number of subjects: 70
Study 22147480 — intervention group
Group type: EXPERIMENTAL
Intervention: Ammonia concentration 12 mg/m3
Number of subjects: 4
Study 22147480 — intervention group
Group type: EXPERIMENTAL
Intervention: Ammonia concentration 21 mg/m3
Number of subjects: 4
Study 22147480 — intervention group
Group type: EXPERIMENTAL
Intervention: Ammonia concentration 34 mg/m3
Number of subjects: 4
Study 22147480 — intervention group
Group type: COMPARATOR
Intervention: Ammonia concentration 4 mg/m3
Number of subjects: 4
Study 19714601 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 259
Study 19714601 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice
Number of subjects: 259
Study 19714601 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapist‐guided treatment
Number of subjects: 259
Study 17065167 — intervention group
Group type: EXPERIMENTAL
Intervention: Oesophageal Doppler (OD) guided optimization of stroke volume (SV)
Number of subjects: 12
Study 17065167 — intervention group
Group type: COMPARATOR
Intervention: Modelflow SV
Number of subjects: 12
Study 17065167 — intervention group
Group type: COMPARATOR
Intervention: Svo2
Number of subjects: 12
Study 17065167 — intervention group
Group type: COMPARATOR
Intervention: FTc
Number of subjects: 12
Study 17065167 — intervention group
Group type: COMPARATOR
Intervention: NIRS (muscle and brain oxygenation)
Number of subjects: 12
Study 15008765 — intervention group
Group type: EXPERIMENTAL
Intervention: Atosiban
Number of subjects: 1431
Study 15008765 — intervention group
Group type: COMPARATOR
Intervention: Hexoprenaline
Number of subjects: 1431
Study 12411844 — intervention group
Group type: EXPERIMENTAL
Intervention: 111In labelled leukocytes (ILLs)
Number of subjects: 16
Study 12411844 — intervention group
Group type: COMPARATOR
Intervention: Control group (6 male patients with urinary tract infections)
Number of subjects: 16
Study 9656849 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide bleaching paste
Number of subjects: 51
Study 9656849 — intervention group
Group type: COMPARATOR
Intervention: Colgate Platinum Professional Overnight Whitening System
Number of subjects: 51
Study 9656849 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 51
Study 9656849 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental agent group
Number of subjects: 51
Study 9656849 — intervention group
Group type: COMPARATOR
Intervention: Colgate Platinum group
Number of subjects: 51
Study 8607569 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine
Number of subjects: 26
Study 8607569 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 8607569 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 26
Study 29355350 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholic drink (n = 48)
Number of subjects: 94
Study 29355350 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink (n = 46)
Number of subjects: 94
Study 28283282 — intervention group
Group type: EXPERIMENTAL
Intervention: docetaxel, prednisone, and custirsen
Number of subjects: 1022
Study 28283282 — intervention group
Group type: COMPARATOR
Intervention: docetaxel and prednisone
Number of subjects: 1022
Study 25673442 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesh group
Number of subjects: 22
Study 25673442 — intervention group
Group type: COMPARATOR
Intervention: Nonmesh group
Number of subjects: 22
Study 23215900 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative care protocol based on The Surviving Sepsis Guidelines
Number of subjects: 629
Study 23215900 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 629
Study 21737063 — intervention group
Group type: EXPERIMENTAL
Intervention: Amine fluoride (Elmex fluid) with laser irradiation (G4)
Number of subjects: 96
Study 21737063 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerium chloride with laser irradiation (G6)
Number of subjects: 96
Study 21737063 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined fluoride/cerium chloride application with laser irradiation (G8)
Number of subjects: 96
Study 21737063 — intervention group
Group type: COMPARATOR
Intervention: Placebo (G1)
Number of subjects: 96
Study 21737063 — intervention group
Group type: EXPERIMENTAL
Intervention: Amine fluoride (G3)
Number of subjects: 96
Study 21737063 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerium chloride (G5)
Number of subjects: 96
Study 21737063 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined cerium chloride and amine fluoride application (G7)
Number of subjects: 96
Study 19934804 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid injection (triamcinolone and lidocaine)
Number of subjects: 36
Study 19934804 — intervention group
Group type: COMPARATOR
Intervention: Saline injection (control)
Number of subjects: 36
Study 17024943 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin composite shades (G1‐Incisal; G2‐A1; G3‐A2; G4‐A3; G5‐A3.5; G6‐A4)
Number of subjects: 60
Study 17024943 — intervention group
Group type: EXPERIMENTAL
Intervention: Enamel margins
Number of subjects: 60
Study 17024943 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentin margins
Number of subjects: 60
Study 12779069 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard eradicating treatment
Number of subjects: 860
Study 12779069 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-month course of empirical treatment
Number of subjects: 860
Study 12779069 — intervention group
Group type: COMPARATOR
Intervention: Functional dyspeptic patients without H. pylori infection
Number of subjects: 860
Study 11060764 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide
Number of subjects: 0
Study 9287924 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprapubic catheterization
Number of subjects: 108
Study 9287924 — intervention group
Group type: COMPARATOR
Intervention: Urethral catheterization
Number of subjects: 108
Study 8308713 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-mg capsule given twice daily
Number of subjects: 37
Study 8308713 — intervention group
Group type: COMPARATOR
Intervention: 1-mg tablet given twice daily
Number of subjects: 37
Study 8308713 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 37
Study 3330140 — intervention group
Group type: EXPERIMENTAL
Intervention: Azapropazone (days 1‐225)
Number of subjects: 93
Study 3330140 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin (1‐28) followed by Allopurinol (29‐225)
Number of subjects: 93
Study 31573689 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol infusion (beta-adrenergic agonist)
Number of subjects: 30
Study 31573689 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-analysis including 724 participants
Number of subjects: 30
Study 29802627 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2% Rosuvastatin gel
Number of subjects: 90
Study 29802627 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% Metformin gel
Number of subjects: 90
Study 29802627 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 90
Study 27244788 — intervention group
Group type: EXPERIMENTAL
Intervention: Students for Nutrition and Exercise intervention
Number of subjects: 1368
Study 27244788 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 1368
Study 24788320 — intervention group
Group type: EXPERIMENTAL
Intervention: Neomycin and rifaximin
Number of subjects: 31
Study 24788320 — intervention group
Group type: COMPARATOR
Intervention: Neomycin and placebo
Number of subjects: 31
Study 22356355 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 0
Study 22356355 — intervention group
Group type: COMPARATOR
Intervention: Control (standard treatment with ICS and LABA)
Number of subjects: 0
Study 20663460 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial (PP) SMBG results to adjust morning medication
Number of subjects: 280
Study 20663460 — intervention group
Group type: COMPARATOR
Intervention: Fasting/preprandial (FP) SMBG results to adjust evening medication
Number of subjects: 280
Study 19726355 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized SIT for 12 months
Number of subjects: 65
Study 19726355 — intervention group
Group type: COMPARATOR
Intervention: Inhaled corticosteroids according to GINA
Number of subjects: 65
Study 15929503 — intervention group
Group type: EXPERIMENTAL
Intervention: Oswestry Standing Frame (n = 71)
Number of subjects: 140
Study 15929503 — intervention group
Group type: COMPARATOR
Intervention: Usual stroke unit care (Control group, n = 69)
Number of subjects: 140
Study 12551705 — intervention group
Group type: EXPERIMENTAL
Intervention: Sigmasporin Microoral
Number of subjects: 30
Study 12551705 — intervention group
Group type: COMPARATOR
Intervention: Sandimmun Neoral
Number of subjects: 30
Study 10608205 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous epidural block with mepivacaine 1.5% initiated 20 min before surgical incision (Pre group)
Number of subjects: 70
Study 10608205 — intervention group
Group type: COMPARATOR
Intervention: Continuous epidural block with mepivacaine 1.5% initiated at completion of surgery (Post group)
Number of subjects: 70
Study 7851604 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate (LA) continued use
Number of subjects: 0
Study 7851604 — intervention group
Group type: COMPARATOR
Intervention: Leuprolide acetate (LA) stopped after 5 days
Number of subjects: 0
Study 1951905 — intervention group
Group type: EXPERIMENTAL
Intervention: Local gentamicin and drainage (Group A)
Number of subjects: 44
Study 1951905 — intervention group
Group type: COMPARATOR
Intervention: Drainage alone (Group B)
Number of subjects: 44
Study 7007179 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine sulfate
Number of subjects: 35
Study 7007179 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 35
Study 30430294 — intervention group
Group type: EXPERIMENTAL
Intervention: Jugular vein access
Number of subjects: 49
Study 30430294 — intervention group
Group type: COMPARATOR
Intervention: Femoral vein access
Number of subjects: 49
Study 30430294 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral vein access by non-expert operators
Number of subjects: 49
Study 30430294 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 49
Study 29866644 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital health intervention using electronic inhaler sensors and a digital health platform for asthma management.
Number of subjects: 207
Study 27206266 — intervention group
Group type: EXPERIMENTAL
Intervention: Mephedrone 200 mg
Number of subjects: 12
Study 27206266 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA 100 mg
Number of subjects: 12
Study 27206266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 24440204 — intervention group
Group type: EXPERIMENTAL
Intervention: Paper Medical Record (PMR)
Number of subjects: 160
Study 24440204 — intervention group
Group type: COMPARATOR
Intervention: Electronic Medical Record (EMR)
Number of subjects: 160
Study 24440204 — intervention group
Group type: COMPARATOR
Intervention: Both PMR and EMR
Number of subjects: 160
Study 24440204 — intervention group
Group type: COMPARATOR
Intervention: EMR
Number of subjects: 160
Study 23020711 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR
Number of subjects: 39
Study 23020711 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 20566676 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 485
Study 20566676 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg dapagliflozin
Number of subjects: 485
Study 20566676 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg dapagliflozin
Number of subjects: 485
Study 20566676 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg dapagliflozin
Number of subjects: 485
Study 17392542 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnamon (1 g/day)
Number of subjects: 72
Study 17392542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 16219189 — intervention group
Group type: EXPERIMENTAL
Intervention: Royal jelly
Number of subjects: 80
Study 16219189 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 11863124 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron supplementation (100 mg every 2 weeks or 1 month)
Number of subjects: 149
Study 10424314 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose (100 mg 3 times daily for 1 year)
Number of subjects: 1027
Study 10424314 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment alone (control group)
Number of subjects: 1027
Study 7591280 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC+GM-CSF
Number of subjects: 30
Study 7591280 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC+G-CSF
Number of subjects: 30
Study 2245919 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric consultation intervention group
Number of subjects: 767
Study 2245919 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly detailed)
Number of subjects: 767
Study 7214785 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 29397442 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy during the first stage of labor
Number of subjects: 104
Study 29397442 — intervention group
Group type: COMPARATOR
Intervention: Standard obstetric care (Control group)
Number of subjects: 104
Study 29397442 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy
Number of subjects: 104
Study 27134066 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing (EMDR)
Number of subjects: 56
Study 27134066 — intervention group
Group type: COMPARATOR
Intervention: Non-Eye Movement Desensitization and Reprocessing (Control)
Number of subjects: 56
Study 24622423 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonconcurrent rehabilitation (N‐CON)
Number of subjects: 11
Study 24622423 — intervention group
Group type: COMPARATOR
Intervention: Concurrent rehabilitation (CON)
Number of subjects: 11
Study 24032205 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular point magnetic sticking (Group A)
Number of subjects: 120
Study 24032205 — intervention group
Group type: EXPERIMENTAL
Intervention: In-pair sticking of magnetic beads at front-back acupoints (Group B)
Number of subjects: 120
Study 24032205 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 120
Study 20492074 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronally advanced flap plus connective tissue graft (CAF+CTG)
Number of subjects: 13
Study 20492074 — intervention group
Group type: COMPARATOR
Intervention: Coronally advanced flap (CAF) alone
Number of subjects: 13
Study 18710446 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg
Number of subjects: 492
Study 18710446 — intervention group
Group type: COMPARATOR
Intervention: Sildenafil 50 mg
Number of subjects: 492
Study 16466168 — intervention group
Group type: EXPERIMENTAL
Intervention: Western medicinal treatment (WM) with additional medication of CHM (modified Huxin Recipe)
Number of subjects: 106
Study 16466168 — intervention group
Group type: COMPARATOR
Intervention: Conventional Western medicinal treatment (WM)
Number of subjects: 106
Study 12645801 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha-2b at 5 MU daily
Number of subjects: 0
Study 12645801 — intervention group
Group type: COMPARATOR
Intervention: Interferon-alpha-2b at 3 MU three times a week (control)
Number of subjects: 0
Study 11192960 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (100 microg) via Easyhaler at a target inspiratory flow of 30 l min(‐1)
Number of subjects: 21
Study 11192960 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol (100 microg) via pressurised metered‐dose inhaler (pMDI) plus spacer
Number of subjects: 21
Study 9170564 — intervention group
Group type: EXPERIMENTAL
Intervention: Single task SRT
Number of subjects: 0
Study 9170564 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual task SRT
Number of subjects: 0
Study 9170564 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation
Number of subjects: 0
Study 9170564 — intervention group
Group type: EXPERIMENTAL
Intervention: SRT (motor-linked test)
Number of subjects: 0